Ingenza Ltd. has achieved a milestone in the development and manufacture of a more cost-effective vaccine against SARS-CoV-2. Ingenza is working with researchers at Oxford University and the UK CPI, Wilton, for the efficient production, using engineered yeast, of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. When displayed on a novel virus-like particle (VLP) – developed and produced by the Oxford team also using a recombinant microbe – the resulting prototype vaccine elicit...